INTRODUCTION
Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus that emerged in 1998 as the causal agent of a respiratory disease and an acute febrile encephalitis in humans (
9,
10). Together with Hendra virus (HeV), identified in Australia in 1994 (
31), and based on unique genetic characteristics distinct from those of other paramyxoviruses, NiV is classified in the genus
Henipavirus, (
15). Further NiV outbreaks have regularly been documented in Bangladesh and India since 2001 (
7,
25). The human death rates varied from 40% in Malaysia to 75% in Bangladesh and India, and a number of outbreaks were associated with interhuman transmission (
21,
27). Several species of fruit bats, primarily of the genus
Pteropus, widely distributed in Australia, Southeast Asia, India, and Africa, appear to be the
Henipavirus reservoir, maintaining a permanent risk of new outbreaks (
11,
22,
38).
The site of primary replication of NiV and the mode of virus propagation throughout the organism remain unknown. The incubation period varies from 4 to 60 days and is shorter in Bangladeshi than in Malaysian patients, potentially reflecting differences between two viral strains (
24,
43). In humans, the blood vessels appear to be one of the early targets of infection, with the central nervous system (CNS) being the most severely affected, although lung, kidney, and other organs are also infected (
43). The majority of human infections led to acute encephalitis with vasculitis-induced thrombosis in the brain and, in some patients, atypical pneumonia and respiratory distress. A late-onset encephalitis could arise up to several months or even years after the initial infection, and a relapsed encephalitis has occurred in patients who had previously recovered from acute encephalitis (
39).
The pathogenesis of Nipah virus infection is poorly understood. We have analyzed the permissiveness of human leukocytes to NiV infection. Only dendritic cells (DC) support a productive NiV infection, although all leukocyte types are capable of binding NiV and transmitting it to susceptible cells in vitro. Accordingly, in the hamster infection model, virus is found associated with leukocytes without signs of infection, and the transfer of these cells resulted in the infection of naïve animals, demonstrating efficient virus transinfection in vivo. We propose that leukocytes act as vehicles for NiV spread within the organism to permissive tissues, contributing to the pathogenesis of NiV infection.
MATERIALS AND METHODS
Cell culture.
Vero E6, 293T, and human U373 astroglioma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 0.1 mg streptomycin, 10 mM HEPES, and 2 mM
l-glutamine at 37°C in 5% CO
2. HPMEC-ST1 (human pulmonary microvascular endothelial cells) (
26) were grown in Endothelial Cell Growth Medium (Promocell) on culture dishes precoated with 0.2% gelatin.
Human peripheral blood was obtained from 20 different healthy donors from the Blood Transfusion Centre (Lyon, France). Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque density gradient centrifugation and then centrifuged through a 50% Percoll gradient (Pharmacia Fine Chemicals, Uppsala, Sweden) for 20 min at 400 × g. Peripheral blood lymphocytes (PBLs) were recovered from the high-density fraction and monocytes from the low-density fraction at the interface. CD3+ and CD19+ lymphocytes and CD14+ monocytes were isolated from the high- and low-density fractions, respectively, using microbeads (Miltenyi Biotech) and magnetic cell separation with a MACS Separator. DC were generated in vitro from the adherent fraction of purified monocytes, treated for 6 days at 5 × 105 monocytes/ml with interleukin 4 (IL-4) (250 U/ml; Peprotech) and graulocyte-macrophage colony-stimulating factor (GM-CSF) (500 U/ml; Peprotech). Macrophages were derived by growth in M-CSF (50 ng/ml; Peprotech) at 37°C-5% CO2 in 6-well plates. PBLs were stimulated overnight with IL-2 (100 U/ml; Abcys) and phytohemagglutinin (PHA) (2 μg/ml; Sigma). The maturation of DC was induced by lipopolysaccharide (LPS) (100 ng/ml; Sigma) for 24 h. Cell purity was verified by flow cytometry after cell labeling with dye-conjugated monoclonal antibodies specific for CD14, CD1, CD11c, CD3, and CD19 (Becton Dickinson) using a FACSCalibur 3C and CellQuestPro software (Becton Dickinson).
Splenocytes were harvested from hamsters and stimulated in culture with concanavalin A (2 μg/ml; Sigma) or left unstimulated. Both human and hamster cells were cultured in complete RPMI medium supplemented with 10% FCS, 100 U/ml penicillin, 0.1 mg streptomycin, 10 mM HEPES, and 2 mM l-glutamine at 37°C in 5% CO2.
Virus infection and titration.
Nipah virus (isolate UMMC1; GenBank AY029767) (
8), recombinant NiV (rNiV), and rNiV-enhanced green fluorescent protein (EGFP) (
44) were prepared on Vero-E9 cells as described previously (
19). Leukocytes were infected at a multiplicity of infection (MOI) of 1, washed twice, and observed by inverted and/or fluorescence microscopy every day postinfection (p.i.) or harvested for RNA isolation or for use in transinfection assays. At the indicated times p.i., 150 μl of cell culture supernatant was collected and frozen prior to viral titration. Viral titration was performed as detailed elsewhere (
19). The viral infection in cocultures of leukocytes with Vero cells was determined using a previously described infectious-center assay (
23).
RNA isolation and reverse transcription-quantitative PCR (RT-qPCR).
RNA was isolated from cells and plasma using an RNeasy Mini Kit (Qiagen) in either RLT or AVL buffer, according to the manufacturer's instructions. Reverse transcription was performed on 0.5 μg of total RNA using oligo(dT) and random-hexamer oligonucleotide primers (iScript cDNA synthesis kit; Bio-Rad) and run in a Biometra T-Gradient PCR device, and cDNAs were diluted 1/10.
Quantitative PCR was performed with all cDNA samples using Platinum SYBR green qPCR SuperMix-UDG with a ROX kit (Invitrogen). qPCR was run on the ABI 7000 PCR system (Applied Biosystems) as follows: 95°C for 5 min and 40 cycles of 95°C for 15 s and 60°C for 1 min, followed by a melting curve up to 95°C at 0.8°C intervals. All samples were run in duplicate, and the results were analyzed using ABI Prism 7000 SDS software. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as a housekeeping gene to normalize the samples. GAPDH and standard references for the corresponding genes were included in each run to check for RNA integrity, RNA load, and inter-PCR variations. After normalization, the results were expressed as the ratio of mRNA copy numbers to the number of copies at time zero (
t = 0) (the fold change); in some experiments, the number of copies of the gene of interest was expressed per μg of analyzed RNA. All calculations were done using the 2
ΔΔCT model (
36), and experiments were performed according to the MIQE guideline (
4). The primers used were designed using Beacon 7.0 software and validated for their efficacy close to 100%: EFNB2 forward, TCGGGCTAGTTAAGGTGTGC, and reverse, ATGAGTGTTCCATGAGTGATGC; EFNB3 forward, TCACCCTCTTGGCTTCTTATCC, and reverse, GGGGAGTGGTTGGTATGAGAG; NiV N forward, GGCAGGATTCTTCGCAACCATC, and reverse, GGCTCTTGGGCCAATTTCTCTG; NiV M forward, AACGGCTGTTTGCTCAAATGGG, and reverse, GCTGCTACTCGGCTGATCTCAC; NiV F forward, GCAGGGCAATCTCACAATCAGG, and reverse, GGACCGATAGCAATGCCTTCAG; NiV G forward, AGGTTCAAAGATCAGCCAGTCG, and reverse, AAAGGGAGTGGGTTAGGACAAG; NiV L forward, ATGGTGCTGTGCTGTCTCAGG, and reverse, AGCCGACATTTCTTGACAACCC; and hGAPDH forward, CACCCACTCCTCCACCTTTGAC, and reverse, GTCCACCACCCTGTTGCTGTAG.
Production of envelope glycoprotein-pseudotyped virus.
NiV G- and F- and control vesicular stomatitis virus (VSV) G-pseudotyped Friend murine leukemia virus (MLV) particles were generated as described elsewhere (
32). Briefly, 293T cells were transfected with the expression vectors pTG534 and pTG13077 (MLV-based transfer vectors coding for GFP), together with either phCMV-VSV-G plasmid coding for VSV G or phCMV-NiV GΔ20 and phCMV-NiV FΔ24 plasmids coding for NiV G with its first N-terminal 20 amino acids (aa) truncated and NiV F with its last C-terminal 24 aa truncated, respectively. Pseudoparticles were concentrated on a 20% sucrose cushion by ultracentrifugation (110,000 ×
g for 2 h; Beckman SW28). The pseudoparticles were used at an MOI of 1 to transduce PHA and IL-2-activated PBLs and cultured in 24-well plates for 48 to 120 h with daily observation under light and fluorescence microscopes.
Transinfection assay.
DC, PBLs, and monocytes were prepared from fresh blood and infected for 1 h with NiV or rNiV-EGFP at either 4°C or 37°C in the presence or absence of 50 μM 5-(
N-ethyl-
N-isopropyl) amiloride (EIPA) (Sigma). In some experiments, 10
6 PBLs were preincubated with 100 μg/ml of EphB4 soluble Fc fusion protein (ligand for ephrinB2; R&D Systems) for 45 min, with 1 mg/ml of pronase (Roche) or 2 mg/ml of trypsin (Sigma) for 30 min at 37°C, or with 5 mM EDTA or 5 mM EGTA (Sigma) for 10 min at room temperature; washed; and infected with NiV. In other experiments, 10
6 PBLs were stripped after infection for 30 min at 4°C with 200 μg/ml pronase. Alternatively, 10
6 PBLs were saturated 24 h p.i. with the anti-NiV G monoclonal antibody (MAb) Nip GIP 1.7 and the anti-NiV F MAb Nip GIP 21 (
20) for 30 min at room temperature. After two washes with cold phosphate-buffered saline (PBS), the cells were cultured at 37°C for up to 96 h and then collected and washed, and 10-fold serial dilutions were added to reporter cell monolayers of either endothelial HPMEC cells or Vero cells for determination of cell-associated infectious NiV, using the infectious-center assay (
23). All experiments were performed with cells obtained from 3 to 7 different donors and analyzed separately.
Infection of hamsters.
Eight-week-old golden hamsters (Mesocricetus auratus; Janvier, France) were anesthetized and infected intraperitoneally (i.p.) with 0.4 ml of NiV or rNiV-EGFP in a biosafety level 4 (BSL-4) laboratory. Blood cells and plasma collected retro-orbitally at 1, 2, 6, and 7 days p.i. were separated by centrifugation and analyzed by RT-PCR for the NiV N gene content and/or determination of infectious NiV. For adoptive transfer, mononuclear spleen leukocytes, obtained after purification on a Ficoll gradient (Eurobio) of splenocytes from infected hamsters (4 days p.i.), were washed and observed under the fluorescence microscope, and the content of cell-associated infectious NiV was followed by coculturing them with Vero cells. In addition, purified cells were injected i.p. into 6 naive hamsters (25 × 105 per hamster). A control group of animals received purified spleen leukocytes from naive hamsters. The animals were followed daily for 2 weeks. All animals were handled in strict accordance with good animal practice as defined by the French national charter on the ethics of animals, and all efforts were made to minimize suffering.
DISCUSSION
We report here that DC are the only human leukocyte type permissive to NiV infection. NiV infection was inhibited by EIPA, suggesting that virus entry into DC occurs via macropinocytosis, an entry pathway recently shown for this virus (
35). The unique permissiveness of DC among the leukocytes is not associated with higher expression of NiV entry receptors, ephrinB2 and ephrinB3 (
1,
33,
34), at least at the transcriptional level, since lymphocytes display higher levels of both mRNAs, but it may reflect constitutive macropinocytosis activity of DC. Although only low levels of infectious virus were observed in DC, they may play a key role in NiV pathogenesis, owing to their high capacity for migration from different viral entry sites to draining lymph nodes, where DC-produced NiV will find new permissive target cells.
The nonpermissiveness of human lymphocytes, monocytes, and macrophages to NiV infection is supported by (i) the lack of accumulation of any NiV gene during infection, (ii) the absence of viral progeny, (iii) the lack of expression of the GFP reporter gene from infectious rNiV-GFP, and (iv) the inability of MLV pseudotypes with NiV G and F to enter these cells. This is in agreement with the inability of the closely related HeV G and F proteins to induce fusion of human lymphocytes or monocytes (
2). Our data suggest that human lymphocytes, monocytes, and macrophages resist NiV infection due to a block at the level of virus entry. NiV infection of macrophages has previously been suggested (
40,
42,
43), but based only on cell morphology, which can hardly exclude DC. Whether macrophages are permissive to NiV infection
in vivo remains to be documented.
Although NiV binds to lymphocytes, it is not internalized, since it can be stripped off by proteolysis and remains sensitive to neutralization by antibodies. The virus stays bound at the cell surface for several days without much loss of infectivity compared to cell-free virus, as if stabilization occurs upon contact with the plasma membrane. Upon contact, cell-bound virus is quickly transferred to a permissive cell. Although monocytes and macrophages attach NiV, their lower level of transinfection may be associated with the high phagocytosis capacity of these cell types, leading to the decreased cell surface exposure of viral particles and their likely inactivation upon endocytosis.
Facilitation of viral spread between different cell types has been reported for other viruses via targeting of C-type lectins, including DC-SIGN, expressed by dendritic cells (
41), as well as L-SIGN, Langerin, and Dectin 1 (
5). It is unlikely that this class of receptors mediates NiV transinfection by lymphocytes because of the resistance of this NiV transmission pathway to calcium chelation and because of the lack of expression of DC-SIGN on T lymphocytes. Our results do not favor a role for ephrinB2 in transinfection and suggest the existence of an alternative attachment membrane protein for NiV that does not seem to induce any internalization signaling upon virus binding. NiV binding to a receptor different from the entry receptor may facilitate its cell membrane localization by avoiding cell fusion and macropinocytosis. Similar cell surface localization of virus during transinfection was demonstrated for
in vitro-derived DC, which transmitted HIV-1 virions to T cells (
6). External HIV virions may remain deeply enmeshed in membrane protrusions and microvilli of the plasma membrane but remained infectious and could be transmitted to target cells without prior internalization (
16). In addition, human B lymphocytes were shown to efficiently transfer cell membrane-bound Epstein-Barr virus to epithelial cells (
37). While DC, macrophages, and B lymphocytes have been demonstrated to mediate virus transinfection, this is, to our knowledge, the first report that T lymphocytes could perform it, as well.
Although transinfection by several viruses of different cell types has been illustrated
in vitro, its
in vivo relevance has yet to be demonstrated. The rapid course of NiV infection, affecting multiple organs, indicates dissemination of the virus via the bloodstream. The present observations argue in favor of leukocytes acting as virus carriers, mediating transinfection of permissive host target cells. Detailed follow-up of virus dissemination within the host after transfer of virus-loaded leukocytes should allow further analysis of leukocytes in NiV spread. Accordingly, in experimentally infected squirrel monkeys, NiV is also detected only associated with PBMC and is not found in plasma (
29). However, occasionally, virus was found in both blood cell and plasma compartments from African green monkeys and cats infected by NiV, although virus detection required RT-PCR with 50 cycles of amplification, suggesting that there was only a very small amount of free virus (
18,
30). In humans, NiV has been isolated from urine and cerebrospinal fluid from infected patients (
12,
13,
43), but there is no report of isolation from serum. Thus, PBMC appear much more appropriate than serum for NiV diagnosis and virus isolation from infected patients. The lymphocyte-bound NiV particles are remarkably stable and retain infectivity for a prolonged period. The ability of leukocytes to transfer virus from infected to noninfected hamsters argues for the
in vivo relevance of cell-mediated transinfection for virus spread throughout the organism. The high trafficking capability of lymphocytes and their constant interaction by rolling onto the endothelial cells could explain disseminated microvascular NiV infection in multiple organs in the absence of detectable viremia. This method of virus propagation may not be unique to NiV but could be used for dissemination of other viruses, such as the closely related Hendra virus, contributing to their high pathogenicity.
These results shed new light on NiV pathogenesis, and we propose a model of its transmission within the host (
Fig. 6). NiV may initially enter the respiratory or digestive tract, potentially via abrasions and breaks in the mucosal surface or skin, where it could infect local DC. Infected DC migrate to regional lymph nodes via the lymphatic vessels, as described for measles, another paramyxovirus, (
14). There, locally produced virus binds to lymphocytes, which subsequently exit the lymph nodes and act as passive vehicles for NiV spread to susceptible cells of the blood vessels of many target organs and possibly enable NiV to cross the blood brain barrier to cause fatal encephalitis. NiV binding to lymphocytes may provide protection to virions and eventually allow their more efficient transport to different tissues, thus playing a critical role in NiV pathogenesis. The leukocyte-bound virus represents a potential target for therapeutic intervention, particularly in the early stages of infection. Indeed, the efficiency of anti-NiV antibodies has been demonstrated in hamsters (
19) and ferrets (
3). Identification of the NiV attachment receptor may provide additional information to better understand NiV-host interaction and potentially open novel therapeutic approaches for this emergent, highly lethal infection.